Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|July 9, 2026

The BioPharm Brief: AI, Answers, and Setbacks

Listen
0:00 / 0:00

Today's BioPharm Brief explores three very different paths toward innovation, from AI-guided precision medicine and a first-in-class autoimmune cell therapy to a late-stage clinical setback in transthyretin amyloid cardiomyopathy.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today, we're looking at three stories that highlight the opportunities and challenges of drug development, including a merger designed to accelerate precision medicine, a new CAR T-cell program for autoimmune disease, and a Phase III trial that fell short of expectations.

Our first story focuses on the growing intersection of artificial intelligence and precision medicine. ChemoMab and Scipher Medicine have announced a merger that will advance nebokitug, a first-in-class anti-CCL24 monoclonal antibody, into an AI-guided Phase II clinical trial for rheumatoid arthritis. The study will use Scipher's molecular profiling platform to identify patients most likely to respond to treatment, reflecting a broader industry shift toward biomarker-driven clinical development. The combined company hopes this precision medicine approach will improve trial efficiency while advancing a novel therapy for patients with rheumatoid arthritis.

Next, AstraZeneca and Ionis Pharmaceuticals reported that Wainua, or eplontersen, did not meet the primary endpoint in the Phase III CARDIO-TTRansform trial for transthyretin-mediated amyloid cardiomyopathy. The investigational RNA-targeted therapy failed to significantly reduce the composite endpoint of cardiovascular death and recurrent cardiovascular events when added to standard of care. While the study demonstrated a safety profile consistent with previous experience and showed encouraging findings in a prespecified subgroup of patients who had not previously received ATTR-CM therapy, the outcome represents a significant setback in the effort to expand Wainua into this indication.

Finally, Fate Therapeutics has received FDA clearance of its investigational new drug application for FT839, an induced pluripotent stem cell-derived dual CAR T-cell therapy for autoimmune diseases. Unlike conventional CAR T therapies that target a single cell type, FT839 is engineered to target both CD19-positive B cells and an additional disease-causing immune cell population. The upcoming Phase I basket trial will evaluate the off-the-shelf cell therapy across multiple autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, ANCA-associated vasculitis, idiopathic inflammatory myopathies, and rheumatoid arthritis. The program represents another step toward expanding cell therapy beyond oncology.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Takeaways

  • New glial biomarker data may help guide the next stage of clinical development for pepinemab in Alzheimer's disease.
  • The FDA has expanded Wilate's indication to include routine prophylaxis for children younger than 6 years with von Willebrand disease.
  • Trutakna becomes the first dual BAFF and APRIL inhibitor approved for IgA nephropathy, introducing a new targeted treatment approach.

Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.